Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 16:13:1043970.
doi: 10.3389/fphar.2022.1043970. eCollection 2022.

Inosine: A bioactive metabolite with multimodal actions in human diseases

Affiliations
Review

Inosine: A bioactive metabolite with multimodal actions in human diseases

In Soo Kim et al. Front Pharmacol. .

Abstract

The nucleoside inosine is an essential metabolite for purine biosynthesis and degradation; it also acts as a bioactive molecule that regulates RNA editing, metabolic enzyme activity, and signaling pathways. As a result, inosine is emerging as a highly versatile bioactive compound and second messenger of signal transduction in cells with diverse functional abilities in different pathological states. Gut microbiota remodeling is closely associated with human disease pathogenesis and responses to dietary and medical supplementation. Recent studies have revealed a critical link between inosine and gut microbiota impacting anti-tumor, anti-inflammatory, and antimicrobial responses in a context-dependent manner. In this review, we summarize the latest progress in our understanding of the mechanistic function of inosine, to unravel its immunomodulatory actions in pathological settings such as cancer, infection, inflammation, and cardiovascular and neurological diseases. We also highlight the role of gut microbiota in connection with inosine metabolism in different pathophysiological conditions. A more thorough understanding of the mechanistic roles of inosine and how it regulates disease pathologies will pave the way for future development of therapeutic and preventive modalities for various human diseases.

Keywords: cancer; cardiovasclar disease; infection; inflammation; inosine; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Inosine generation in the body and its effect. Inosine originates either within or outside the body. Three different reactions produce endogenous inosine: ①Hydrolytic deamination of adenosine by adenosine deaminase (ADA), ② dephosphorylation of inosine monophosphate (IMP) by 5′-nucleotidase (5′NT), and ③ reaction of hypoxanthine and ribose-1-phosphate (R1P) by purine nucleoside phosphorylase (PNP). Exogenous inosine is from two ways: ④ Supplementation such as isoprinosine or inosine acedoben dimepranol (IAD) or ⑤ secretion from gut microbiota. Inosine has various effects on the body.

Similar articles

Cited by

References

    1. Abdelkader N. F., Ibrahim S. M., Moustafa P. E., Elbaset M. A. (2022). Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TFG-β/PKC/TRPV1 signaling pathways. Biomed. Pharmacother. 145, 112395. 10.1016/j.biopha.2021.112395 - DOI - PubMed
    1. Akedo H., Nishihara H., Shinkai K., Komatsu K., Ishikawa S. (1972). Multiple forms of human adenosine deaminase. I. Purification and characterization of two molecular species. Biochim. Biophys. Acta 276 (1), 257–271. 10.1016/0005-2744(72)90028-9 - DOI - PubMed
    1. Akeson A. L., Wiginton D. A., Dusing M. R., States J. C., Hutton J. J. (1988). Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts. J. Biol. Chem. 263 (31), 16291–16296. 10.1016/s0021-9258(18)37591-4 - DOI - PubMed
    1. Ames B. N., Cathcart R., Schwiers E., Hochstein P. (1981). Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci. U. S. A. 78 (11), 6858–6862. 10.1073/pnas.78.11.6858 - DOI - PMC - PubMed
    1. Ascherio A., LeWitt P. A., Xu K., Eberly S., Watts A., Matson W. R., et al. (2009). Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66 (12), 1460–1468. 10.1001/archneurol.2009.247 - DOI - PMC - PubMed